Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP

A. Santoro, S. Viviani, C. J R Villarreal, V. Bonfante, A. Delfino, P. Valagussa, G. Bonadonna

Research output: Contribution to journalArticle

Abstract

One hundred and twenty-two consecutive patients with Hodgkin's disease who relapsed after primary curative irradiation were treated with either MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) or a doxorubicin-containing regimen (ADM-Reg). The main pretreatment characteristics were comparable in the two groups. Complete remission was achieved in 74.6% of patients treated with MOPP (44 of 59) and in 90.5% of those given ADM-Reg (57 of 63). No difference was observed in the incidence of complete remission with regard to the type of ADM-Reg utilized [MABOP (mechlorethamine, doxorubicin, bleomycin, vincristine, and prednisone), 92.9%; ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), 95.6%; and MOPP alternated with ABVD, 84.6%]. The superiority of ADM-Reg versus MOPP was also confirmed in the 7-year analysis of freedom from disease progression (73.2% vs 42.2%), relapse-free survival (81.2% vs 54.3%), and overall survival (80.5% vs 44.4%). Thrombocytopenia was less frequently observed with ADM-Reg (30%), particularly following ABVD (13%), compared to MOPP (73%). The lowest incidence of alopecia occurred in patients given MOPP (15%) or MOPP/ABVD (19%). Acute nonlymphoblastic leukemia was observed in patients treated with MOPP (five of 59) and MABOP (one of 14). The observed findings indicate that in patients failing to respond to primary radiotherapy, salvage regimens containing doxorubicin are more effective than MOPP. Furthermore, combinations devoid of procarbazine and alkylating agents (ABVD) or with less intensive administration of these drugs (MOPP/ABVD) were not associated with secondary leukemia.

Original languageEnglish
Pages (from-to)343-348
Number of pages6
JournalCancer Treatment Reports
Volume70
Issue number3
Publication statusPublished - 1986

Fingerprint

Procarbazine
Mechlorethamine
Vincristine
Prednisone
Hodgkin Disease
Doxorubicin
Drug Therapy
Bleomycin
Dacarbazine
Survival
Vinblastine
Alkylating Agents
Alopecia
Incidence
Acute Myeloid Leukemia
Thrombocytopenia
Disease Progression
Leukemia
Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Santoro, A., Viviani, S., Villarreal, C. J. R., Bonfante, V., Delfino, A., Valagussa, P., & Bonadonna, G. (1986). Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP. Cancer Treatment Reports, 70(3), 343-348.

Salvage chemotherapy in Hodgkin's disease irradiation failures : Superiority of doxorubicin-containing regimens over MOPP. / Santoro, A.; Viviani, S.; Villarreal, C. J R; Bonfante, V.; Delfino, A.; Valagussa, P.; Bonadonna, G.

In: Cancer Treatment Reports, Vol. 70, No. 3, 1986, p. 343-348.

Research output: Contribution to journalArticle

Santoro, A, Viviani, S, Villarreal, CJR, Bonfante, V, Delfino, A, Valagussa, P & Bonadonna, G 1986, 'Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP', Cancer Treatment Reports, vol. 70, no. 3, pp. 343-348.
Santoro, A. ; Viviani, S. ; Villarreal, C. J R ; Bonfante, V. ; Delfino, A. ; Valagussa, P. ; Bonadonna, G. / Salvage chemotherapy in Hodgkin's disease irradiation failures : Superiority of doxorubicin-containing regimens over MOPP. In: Cancer Treatment Reports. 1986 ; Vol. 70, No. 3. pp. 343-348.
@article{fb0acfc8bfa545deae85d40cce2fc75c,
title = "Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP",
abstract = "One hundred and twenty-two consecutive patients with Hodgkin's disease who relapsed after primary curative irradiation were treated with either MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) or a doxorubicin-containing regimen (ADM-Reg). The main pretreatment characteristics were comparable in the two groups. Complete remission was achieved in 74.6{\%} of patients treated with MOPP (44 of 59) and in 90.5{\%} of those given ADM-Reg (57 of 63). No difference was observed in the incidence of complete remission with regard to the type of ADM-Reg utilized [MABOP (mechlorethamine, doxorubicin, bleomycin, vincristine, and prednisone), 92.9{\%}; ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), 95.6{\%}; and MOPP alternated with ABVD, 84.6{\%}]. The superiority of ADM-Reg versus MOPP was also confirmed in the 7-year analysis of freedom from disease progression (73.2{\%} vs 42.2{\%}), relapse-free survival (81.2{\%} vs 54.3{\%}), and overall survival (80.5{\%} vs 44.4{\%}). Thrombocytopenia was less frequently observed with ADM-Reg (30{\%}), particularly following ABVD (13{\%}), compared to MOPP (73{\%}). The lowest incidence of alopecia occurred in patients given MOPP (15{\%}) or MOPP/ABVD (19{\%}). Acute nonlymphoblastic leukemia was observed in patients treated with MOPP (five of 59) and MABOP (one of 14). The observed findings indicate that in patients failing to respond to primary radiotherapy, salvage regimens containing doxorubicin are more effective than MOPP. Furthermore, combinations devoid of procarbazine and alkylating agents (ABVD) or with less intensive administration of these drugs (MOPP/ABVD) were not associated with secondary leukemia.",
author = "A. Santoro and S. Viviani and Villarreal, {C. J R} and V. Bonfante and A. Delfino and P. Valagussa and G. Bonadonna",
year = "1986",
language = "English",
volume = "70",
pages = "343--348",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "3",

}

TY - JOUR

T1 - Salvage chemotherapy in Hodgkin's disease irradiation failures

T2 - Superiority of doxorubicin-containing regimens over MOPP

AU - Santoro, A.

AU - Viviani, S.

AU - Villarreal, C. J R

AU - Bonfante, V.

AU - Delfino, A.

AU - Valagussa, P.

AU - Bonadonna, G.

PY - 1986

Y1 - 1986

N2 - One hundred and twenty-two consecutive patients with Hodgkin's disease who relapsed after primary curative irradiation were treated with either MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) or a doxorubicin-containing regimen (ADM-Reg). The main pretreatment characteristics were comparable in the two groups. Complete remission was achieved in 74.6% of patients treated with MOPP (44 of 59) and in 90.5% of those given ADM-Reg (57 of 63). No difference was observed in the incidence of complete remission with regard to the type of ADM-Reg utilized [MABOP (mechlorethamine, doxorubicin, bleomycin, vincristine, and prednisone), 92.9%; ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), 95.6%; and MOPP alternated with ABVD, 84.6%]. The superiority of ADM-Reg versus MOPP was also confirmed in the 7-year analysis of freedom from disease progression (73.2% vs 42.2%), relapse-free survival (81.2% vs 54.3%), and overall survival (80.5% vs 44.4%). Thrombocytopenia was less frequently observed with ADM-Reg (30%), particularly following ABVD (13%), compared to MOPP (73%). The lowest incidence of alopecia occurred in patients given MOPP (15%) or MOPP/ABVD (19%). Acute nonlymphoblastic leukemia was observed in patients treated with MOPP (five of 59) and MABOP (one of 14). The observed findings indicate that in patients failing to respond to primary radiotherapy, salvage regimens containing doxorubicin are more effective than MOPP. Furthermore, combinations devoid of procarbazine and alkylating agents (ABVD) or with less intensive administration of these drugs (MOPP/ABVD) were not associated with secondary leukemia.

AB - One hundred and twenty-two consecutive patients with Hodgkin's disease who relapsed after primary curative irradiation were treated with either MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) or a doxorubicin-containing regimen (ADM-Reg). The main pretreatment characteristics were comparable in the two groups. Complete remission was achieved in 74.6% of patients treated with MOPP (44 of 59) and in 90.5% of those given ADM-Reg (57 of 63). No difference was observed in the incidence of complete remission with regard to the type of ADM-Reg utilized [MABOP (mechlorethamine, doxorubicin, bleomycin, vincristine, and prednisone), 92.9%; ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), 95.6%; and MOPP alternated with ABVD, 84.6%]. The superiority of ADM-Reg versus MOPP was also confirmed in the 7-year analysis of freedom from disease progression (73.2% vs 42.2%), relapse-free survival (81.2% vs 54.3%), and overall survival (80.5% vs 44.4%). Thrombocytopenia was less frequently observed with ADM-Reg (30%), particularly following ABVD (13%), compared to MOPP (73%). The lowest incidence of alopecia occurred in patients given MOPP (15%) or MOPP/ABVD (19%). Acute nonlymphoblastic leukemia was observed in patients treated with MOPP (five of 59) and MABOP (one of 14). The observed findings indicate that in patients failing to respond to primary radiotherapy, salvage regimens containing doxorubicin are more effective than MOPP. Furthermore, combinations devoid of procarbazine and alkylating agents (ABVD) or with less intensive administration of these drugs (MOPP/ABVD) were not associated with secondary leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0022608592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022608592&partnerID=8YFLogxK

M3 - Article

C2 - 2420444

AN - SCOPUS:0022608592

VL - 70

SP - 343

EP - 348

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 3

ER -